Arca
Skip to content

PDUFA Calendar

The dates by which FDA has committed to decide on a drug, as companies have announced them.

FDA does not publish the dates by which it has agreed to decide on a drug; companies announce them. These are the dates companies have disclosed in their SEC filings, each with the filing's own sentence, and the advisory committee meetings ahead.

  • Decision dates in the next 90 days: 19
  • Next: Deramiocel, Capricor Therapeutics, Inc.: Nov 22, 2026
  • Advisory committee meetings ahead: 1

Decision Dates by Month

Disclosed PDUFA dates in the next twelve months, as of Nov 17, 2026. Companies announce most dates within a year of the decision, so later months fill in.

Upcoming Decision Dates

41 disclosed dates ahead, soonest first. Each filing link opens the source; hover it to read the company's own sentence.
in 5 daysDeramiocelupper limb impairment in patients 9 years old
Capricor Therapeutics, Inc.
BLA8-K filed Nov 10, 2026
in 10 daysBBP-418NDA10-Q filed Oct 29, 2026
in 11 daysD-PLEX 100
PolyPid Ltd.
NDA6-K filed Nov 12, 2026
in 13 dayspovetaciceptIgA nephropathy
Jade Biosciences, Inc.
Zai Lab Ltd
BLA10-Q filed Nov 3, 2026
in 13 daysbezuclastinibgastrointestinal stromal tumor
Cogent Biosciences, Inc.
—8-K filed Aug 10, 2026
in 25 daysimsidolimabgeneralized pustular psoriasis (GPP)
Anaptysbio, Inc.
BLA10-Q filed Nov 12, 2026
in 30 daysrelacorilantCushing's syndromeNDA8-K filed Nov 3, 2026
in 35 dayslorundrostat
Mineralys Therapeutics, Inc.
NDA10-Q filed Nov 4, 2026
in 36 daysanito-celmultiple myeloma
Arcellx, Inc.
BLA10-Q filed Aug 6, 2026
in 40 daysrelutrigine
Praxis Precision Medicines, Inc.
NDA10-Q filed Nov 9, 2026
in 43 daysbezuclastinibnon-advanced systemic mastocytosis
Cogent Biosciences, Inc.
—8-K filed Aug 10, 2026
in 48 daysIBTROZIsNDA8-K filed Nov 4, 2026
in 65 daysZeleciment rostudirsenDuchenne muscular dystrophy (DMD)
Dyne Therapeutics, Inc.
BLA8-K filed Nov 5, 2026
in 72 daysARIKAYCEMAC lung diseasesNDA10-Q filed Oct 29, 2026
in 73 daysulixacaltamide HClessential tremor
Praxis Precision Medicines, Inc.
NDA10-Q filed Nov 9, 2026
in 74 daysJoenjaAPDSsNDA6-K filed Sep 25, 2026
in 77 daysYeztugo (lenacapavir)HIV pre-exposure prophylaxis (PrEP)sNDA10-Q filed Aug 6, 2026
in 79 daysinfigratinibNDA10-Q filed Oct 29, 2026
in 87 daystinlarebantStargardt disease type 1 (STGD1)
Belite Bio, Inc.
NDA6-K filed Nov 12, 2026
in 98 daysZORYVE cream 0.05%atopic dermatitis in infants down to 3 months of agesNDA8-K filed Nov 4, 2026
in 102 dayszipalertinibrelapsed epidermal growth factor receptor exon 20 insertion non-small cell lung cancer
Cullinan Therapeutics, Inc.
NDA8-K filed Nov 10, 2026
in 103 daysQTORIN Rapamycinmicrocystic lymphatic malformations
Palvella Therapeutics, Inc.
—8-K filed Nov 5, 2026
in 103 daysVOXZOGOachondroplasiasNDA10-Q filed Nov 3, 2026
in 106 daysZanzalintinibpreviously treated metastatic colorectal cancer—8-K filed Oct 29, 2026
in 113 daysLonvoguran Ziclumeran (Lonvo-z)Hereditary Angioedema (HAE)
Intellia Therapeutics, Inc.
BLA8-K/A filed Nov 13, 2026
in 119 daysAnaphylm (dibutepinephrine)Type I allergic reactions, including anaphylaxisNDA8-K filed Oct 15, 2026
in 135 daysPitolisant GR
Harmony Biosciences Holdings, Inc.
NDA10-Q filed Nov 4, 2026
in 148 daysozekibartconventional chondrosarcoma
Inhibrx Biosciences, Inc.
BLA8-K filed Aug 13, 2026
in 150 daysoral cannabidiol capsule formulationNDA8-K filed Nov 2, 2026
in 156 daysIdvynsoHIV-1 infectionsNDA10-Q filed Nov 4, 2026
in 157 daysDeucrictibant IR
Pharvaris N.V.
NDA6-K filed Aug 12, 2026
in 162 daysvaregacestat
Immunome Inc.
NDA10-Q filed Nov 9, 2026
in 165 daysifezuntirgene inilparvovec
uniQure N.V.
BLA10-Q filed Nov 4, 2026
in 165 daysAXS-12cataplexy in narcolepsyNDA10-Q filed Nov 2, 2026
in 172 daysencaleretNDA10-Q filed Oct 29, 2026
in 177 daysMezigdomide—8-K filed Oct 29, 2026
in 191 daysobexelimabImmunoglobulin G4-Related Disease (IgG4-RD)
Zenas BioPharma, Inc.
BLA8-K filed Nov 5, 2026
in 192 daysKHINDIVIsNDA8-K filed Nov 5, 2026
in 194 daysVOXZOGOhypochondroplasiasNDA10-Q filed Nov 3, 2026
in 209 daysUGN-103recurrent low-grade intermediate risk NMIBCNDA10-Q filed Nov 4, 2026
in 219 daysralinepagPAH
Liquidia Corp
NDA10-Q filed Nov 10, 2026

Advisory Committee Meetings Ahead

Meetings FDA has noticed in the Federal Register, soonest first
MeetingCommitteeOn the agendaSubmitted by
Microbiology Devices PanelThe meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On November 19, …—

Recent Decision Dates

Dates in the last 90 days, newest first. A passed date is not a decision: check the drug's page or the company's later filings.
3 days agoMYQORZOhypertrophic cardiomyopathysNDA8-K filed May 5, 2026
3 days agoivonescimab
Summit Therapeutics Inc.
BLA8-K filed Jul 23, 2026
16 days agomitapivatsickle cell diseasesNDA10-Q filed Jul 30, 2026
18 days agoINO-3107recurrent respiratory papillomatosis
Inovio Pharmaceuticals, Inc.
BLA10-Q filed Aug 12, 2026
22 days agobepirovirsen—10-Q filed Jul 29, 2026
31 days agoPhentolamine Ophthalmic Solution 0.75%presbyopia
Opus Genetics, Inc.
sNDA8-K filed Mar 10, 2026
48 days agoapitegromabBLA10-Q filed Aug 6, 2026
51 days agorelutrigineSCN2A and SCN8A developmental and epileptic encephalopathies
Praxis Precision Medicines, Inc.
NDA10-Q filed Nov 9, 2026
52 days agozilurgisertibfibrodysplasia ossificans progressivaNDA8-K filed Aug 5, 2026
56 days agozilganersen—10-Q filed Jul 29, 2026
59 days agoUX111 (rebisufligene etisparvovec)Sanfilippo syndrome type A (MPS IIIA)BLA8-K filed Aug 4, 2026
60 days agozidesamtinibTKI pre-treated locally advanced or metastatic ROS1-positive non-small cell lung cancerNDA10-Q filed May 7, 2026
67 days agoPixclara—6-K filed Aug 20, 2026
82 days agobictegravir and lenacapavirvirologically suppressed HIVNDA10-Q filed Aug 6, 2026
84 days agoZiihera (zanidatamab-hrii)first-line treatment of HER2-positive locally advanced or metastatic GEA, including cancers of the stomach, gastroesophageal junction and esophagus, in combination with chemotherapy, with or without tislelizumab
Zymeworks Inc.
sBLA8-K filed Aug 6, 2026
85 days agoLEQEMBI IQLIK (lecanemab)sBLA10-Q filed Jul 29, 2026
86 days agoDTX401GSDIaBLA8-K filed Aug 4, 2026

Read weekly from companies' 8-K, 6-K and 10-Q filings. A language model reads each sentence for the product and date; a date is listed only when the product and the date both appear in the sentence it came from, and the newest filing wins, so an extension replaces the old date. SEC EDGAR full-text search · Updated Nov 17, 2026

About this data

What a PDUFA date is

Under the Prescription Drug User Fee Act, FDA commits to act on most applications by a goal date: about ten months after filing for a standard review and six for a priority review, counted from when FDA accepts the application. FDA can approve before the date, extend it by three months after a major amendment, or issue a complete response letter instead of an approval. A date is a target, not a promised decision.

What this calendar misses

Only dates a company put in an SEC filing. Private companies, companies outside SEC reporting and many supplemental applications never disclose theirs, and some companies give only a quarter. FDA's own advisory committee calendar is here; published decisions FDA has explained are in the complete response letters.

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.